Editas Medicine, Inc. (NASDAQ:EDIT) is a biotechnology company focused on developing gene-editing technologies. As a clinical-stage company, Editas is heavily invested in research and development (R&D) to bring its innovative therapies to market. This investment phase often results in financial metrics that reflect high costs and low immediate returns, a common scenario in the biotech industry.

Editas Medicine's Return on Invested Capital (ROIC) is -90.41%, while its Weighted Average Cost of Capital (WACC) is 12.13%. This results in a ROIC to WACC ratio of -7.45, indicating that the company is not currently generating returns that exceed its cost of capital. This is typical for clinical-stage biotech companies that are investing heavily in R&D without yet having commercialized products.

In comparison, Intellia Therapeutics, Inc. (NTLA) has a ROIC of -59.31% and a WACC of 12.02%, resulting in a ROIC to WACC ratio of -4.93. CRISPR Therapeutics AG (CRSP) shows a ROIC of -23.22% and a WACC of 11.75%, with a ROIC to WACC ratio of -1.98, the least negative among its peers. Beam Therapeutics Inc. (BEAM) and Pacific Biosciences of California, Inc. (PACB) also exhibit negative ROICs, with ratios of -2.51 and -13.81, respectively.

CRISPR Therapeutics AG stands out with the highest ROIC to WACC ratio of -1.98 among its peers. Although still negative, this ratio suggests that CRISPR Therapeutics is closer to achieving a balance between its returns and cost of capital compared to its peers. This could indicate a more favorable position in terms of financial efficiency and potential for future profitability.

Overall, all companies in this analysis are operating with negative ROICs, which is typical for biotech companies in the development phase. However, the varying degrees of ROIC to WACC ratios highlight differences in financial efficiency and potential for future success among these companies.